Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy
© 2023. The Author(s)..
COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for antibodies targeting relatively conserved regions, individually e.g. sotrovimab. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to detect emerging drug resistance in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the antibody epitopes and for casirivimab+imdevimab multiple mutations are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
---|---|
Enthalten in: |
Nature communications - 14(2023), 1 vom: 07. Juni, Seite 3334 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ragonnet-Cronin, Manon [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Monoclonal |
---|
Anmerkungen: |
Date Completed 09.06.2023 Date Revised 14.02.2024 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1038/s41467-023-37826-w |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM357883985 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM357883985 | ||
003 | DE-627 | ||
005 | 20240214232719.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41467-023-37826-w |2 doi | |
028 | 5 | 2 | |a pubmed24n1292.xml |
035 | |a (DE-627)NLM357883985 | ||
035 | |a (NLM)37286554 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ragonnet-Cronin, Manon |e verfasserin |4 aut | |
245 | 1 | 0 | |a Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 09.06.2023 | ||
500 | |a Date Revised 14.02.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2023. The Author(s). | ||
520 | |a COVID-19 patients at risk of severe disease may be treated with neutralising monoclonal antibodies (mAbs). To minimise virus escape from neutralisation these are administered as combinations e.g. casirivimab+imdevimab or, for antibodies targeting relatively conserved regions, individually e.g. sotrovimab. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approach to detect emerging drug resistance in Delta and Omicron cases treated with casirivimab+imdevimab and sotrovimab respectively. Mutations occur within the antibody epitopes and for casirivimab+imdevimab multiple mutations are present on contiguous raw reads, simultaneously affecting both components. Using surface plasmon resonance and pseudoviral neutralisation assays we demonstrate these mutations reduce or completely abrogate antibody affinity and neutralising activity, suggesting they are driven by immune evasion. In addition, we show that some mutations also reduce the neutralising activity of vaccine-induced serum | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
700 | 1 | |a Nutalai, Rungtiwa |e verfasserin |4 aut | |
700 | 1 | |a Huo, Jiandong |e verfasserin |4 aut | |
700 | 1 | |a Dijokaite-Guraliuc, Aiste |e verfasserin |4 aut | |
700 | 1 | |a Das, Raksha |e verfasserin |4 aut | |
700 | 1 | |a Tuekprakhon, Aekkachai |e verfasserin |4 aut | |
700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
700 | 1 | |a Selvaraj, Muneeswaran |e verfasserin |4 aut | |
700 | 1 | |a Groves, Natalie |e verfasserin |4 aut | |
700 | 1 | |a Hartman, Hassan |e verfasserin |4 aut | |
700 | 1 | |a Ellaby, Nicholas |e verfasserin |4 aut | |
700 | 1 | |a Mark Sutton, J |e verfasserin |4 aut | |
700 | 1 | |a Bahar, Mohammad W |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Daming |e verfasserin |4 aut | |
700 | 1 | |a Fry, Elizabeth |e verfasserin |4 aut | |
700 | 1 | |a Ren, Jingshan |e verfasserin |4 aut | |
700 | 1 | |a Brown, Colin |e verfasserin |4 aut | |
700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
700 | 1 | |a Hopkins, Susan |e verfasserin |4 aut | |
700 | 1 | |a Chand, Meera |e verfasserin |4 aut | |
700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
700 | 1 | |a Rokadiya, Sakib |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 14(2023), 1 vom: 07. Juni, Seite 3334 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
773 | 1 | 8 | |g volume:14 |g year:2023 |g number:1 |g day:07 |g month:06 |g pages:3334 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-023-37826-w |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 14 |j 2023 |e 1 |b 07 |c 06 |h 3334 |